RT Journal Article
T1 Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19.
A1 Collazos, Julio
A1 Domingo, Pere
A1 Fernandez-Araujo, Nerio
A1 Asensi-Diaz, Elia
A1 Vilchez-Rueda, Helem
A1 Lalueza, Antonio
A1 Roy-Vallejo, Emilia
A1 Blanes, Rosa
A1 Raya-Cruz, Manuel
A1 Sanz-Canovas, Jaime
A1 Artero, Arturo
A1 Ramos-Rincon, Jose-Manuel
A1 Dueñas-Gutierrez, Carlos
A1 Lamas-Ferreiro, Jose Luis
A1 Asensi, Victor
K1 Severity of Illness Index
K1 Spain
K1 Treatment Outcome
K1 Valproic Acid
K1 COVID-19 Drug Treatment
AB Valproic acid (VPA) has shown beneficial effects in vitro against SARS-CoV-2 infection, but no study has analyzed its efficacy in the clinical setting. This multicenter, retrospective study included 165 adult patients receiving VPA at the time of admission to hospital, and 330 controls matched for sex, age and date of admission. A number of clinical, outcome and laboratory parameters were recorded to evaluate differences between the two groups. Four major clinical endpoints were considered: development of lung infiltrates, in-hospital respiratory worsening, ICU admissions and death. VPA-treated patients had higher lymphocyte (P VPA-treated patients seem to develop less serious COVID-19 than control patients, according to diverse clinical endpoints and laboratory markers.
PB Public Library of Science
YR 2022
FD 2022-01-27
LK http://hdl.handle.net/10668/20415
UL http://hdl.handle.net/10668/20415
LA en
NO Collazos J, Domingo P, Fernández-Araujo N, Asensi-Díaz E, Vilchez-Rueda H, Lalueza A, et al. Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS One. 2022 Jan 27;17(1):e0262777
DS RISalud
RD Apr 5, 2025